肿瘤细胞治疗研究
英文原题：CD70-Targeted Radiotheranostics: Now and Future.
分化簇 70（CD70）是由 TNFSF7 编码的跨膜糖蛋白，属于肿瘤坏死因子（TNF）超家族成员，并作为共刺激受体 CD27 的配体。
分化簇70（CD70）是由TNFSF7编码的跨膜糖蛋白，属于肿瘤坏死因子（TNF）超家族，是共刺激受体CD27的配体。CD70在多种恶性肿瘤中异常过表达，包括透明细胞肾细胞癌（ccRCC）和鼻咽癌（NPC）。靶向CD70的放射诊疗一体化或可应对抗体药物偶联物（ADC）和CAR-T（CAR-T）疗法面临的耐药、肿瘤穿透受限等关键难题，但这一治疗策略尚未进入临床应用。本综述概述CD70在正常组织和器官以及不同肿瘤中的表达，并介绍近期临床试验中靶向CD70的免疫PET/CT成像所取得的积极结果。此外，我们总结当前处于临床前或临床试验阶段的相关治疗性放射性药物，为未来开发靶向CD70的放射诊疗一体化方案提供合理路线图。
The cluster of differentiation 70 (CD70), a transmembrane glycoprotein encoded by TNFSF7, is a member of the tumor necrosis factor (TNF) superfamily and serves as the ligand for the co-stimulatory receptor CD27. It is aberrantly overexpressed in various malignancies, including clear cell renal cell carcinoma (ccRCC) and nasopharyngeal carcinoma (NPC). Although CD70-directed radiotheranostics may address key challenges faced by antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) therapies, such as drug resistance and tumor penetration barriers, this therapeutic approach remains unexplored in clinical settings. In this review, we highlight the expression of CD70 in normal tissues and organs, as well as in different tumor types, presenting promising results from CD70-targeted immuno-PET/CT imaging in recent clinical trials. Furthermore, we emphasize relevant therapeutic radiopharmaceuticals currently in preclinical or clinical trials, providing a rational roadmap for guiding future development of CD70-targeted radiotheranostics.
MEMBER ACCOUNT
登录成功会直接打开下一页。
